How Value Investors Can Evaluate Bio-Tech Companies [VIDEO]


Value investors are well aware that investing in technology companies is not an easy task. Additionally, valuing bio-tech companies is far more difficult. The Manual of Ideas conducted an interview with Humphrey Nokes of Cygna Negra, on this very topic. Nokes discusses how value investors can evaluate bio-tech companies in this video interview:

Updated on

Seth Klarman’s 2021 Letter: Baupost’s “Never-Ending” Hunt For Information

Baupost's investment process involves "never-ending" gleaning of facts to help support investment ideas Seth Klarman writes in his end-of-year letter to investors. In the letter, a copy of which ValueWalk has been able to review, the value investor describes the Baupost Group's process to identify ideas and answer the most critical questions about its potential Read More

No posts to display